BRITISH COLUMBIA, Canada, July 31 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc., (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF)
(http://www.ixsbio.com), a drug development company commercializing the next
generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) technology, will present at IBC's 13th Annual World Congress Drug
Discovery & Development of Innovative Therapeutics (DDT) Conference being held
in Boston at the World Trade Center Boston & Seaport Hotel. The InNexus
presentation will be within the Main Conference beginning at 9:40 AM (ET) on
Wednesday, August 6th, held in the amphitheater at the World Trade Center
Boston.
Dr. Thomas Kindt, Chief Scientific Officer will present an in-depth
presentation on a Case Study of InNexus' preclinical candidate DXL625 (CD20):
A New Platform for Augmenting Antibody Therapeutics for Cancer. Chairman and
CEO, Jeff Morhet will also provide a company overview, including information
about InNexus' unique business strategy, its DXL(TM) technology platform and
upcoming company milestones. Investors, venture capitalists, company
executives, scientists and other industry leaders will attend the conferences.
About InNexus
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, that may cause actual
results or performance to differ materially from those currently anticipated
in such statements.
SOURCE InNexus Biotechnology Inc.